Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
CORE PRINCIPLE / WORLD VISION
CORE PRINCIPLE / WORLD VISION
VALUES
VALUES
History
History of Santen
Corporate Executives
Top Management
Corporate Executive
Corporate Governance
Corporate Governance
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
Santen 2030
Santen 2030
Medium-term Management Plan
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Safety
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Product Process: R&D
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Quality Compliance
The Ophthalmic Production Process: Production
Sales & Marketing
Sales & Marketing
Our Stories
Sustainability
Sustainability at Santen
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Digital Transformation (DX)
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Environment
Measures against Climate Change
Environmental Load Reduction
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Santen Initiatives
Santen Activities for Inclusive Society
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environmental Data 2022
Employment and Human Resources Data 2022
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
2023
2023 News
Press Release
IR News
Information
Press Release
03.27.2023
Santen Files for Manufacturing and Marketing Approval for STN1011402 (Epinastine Hydrochloride) Ophthalmic Cream in Japan - Applied once daily to periocular area, new formulation for treatment of allergic conjunctivitis-
03.01.2023
Notice of Corporate Officer Change
02.08.2023
Santen Announces China NMPA Acceptance of STN1011101 Marketing Authorization Application in Patients with Open-Angle Glaucoma or Increased Intraocular Eye Pressure
Press Release
IR News
03.27.2023
Santen Files for Manufacturing and Marketing Approval for STN1011402 (Epinastine Hydrochloride) Ophthalmic Cream in Japan - Applied once daily to periocular area, new formulation for treatment of allergic conjunctivitis-
03.27.2023
Santen Announces Completion of Share Buyback and Number of Shares to be Canceled
03.22.2023
Santen Announces Cancellation of Treasury Shares
03.01.2023
Notice of Corporate Officer Change
03.01.2023
Santen Announces Status of Share Buyback
IR News
Information
02.07.2023
Santen selected as "The Sustainability Yearbook Member" by S&P Global in the United States
Information
News Archive
